Related Experiment Video
Updated: Jul 18, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
MGMT methylation: a marker of response to temozolomide in low-grade gliomas
Sibille Everhard1, Gentian Kaloshi, Emmanuelle Crinière
1Institut National de la Sante et de la Recherche Médicale, U711, Paris, France.
Abstract:
The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP was detected in 63 of 68 (92.6 %) patients and was a favorable predictor of progression-free survival as compared with unmethylated MGMTP tumors (p < 0.0001). Assessment of MGMTP status could help identifying low-grade gliomas patients more likely to respond to chemotherapy or to benefit from MGMT depletion strategies.
